NEW YORK (GenomeWeb News) – Roche NimbleGen said this week that it has entered into a partnership with the Korea Centers for Disease Control and sequencing services firm Macrogen to conduct an eight-month copy number variation study of Korean individuals. According to Roche, the two-phase study will include large-scale characterization of CNVs in Korean populations and analysis of common CNVs in genome-wide association studies for complex disease including diabetes.